AGEN: Agenus, Inc. Price to Sales
Agenus leads in immuno-oncology, raising capital through licensing agreements and partner milestone payments. The price-to-sales ratio reflects the business valuation dynamics, where the value of 2.30 serves as the current metric. A team of top scientists is developing innovative anti-cancer agents. To mitigate the risks of platform dependency, Agenus is monetizing legacy patents by selling royalties to global pharma behemoths.
Metric breakdowns and analytics for Agenus Inc (AGEN)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
AGEN - Net Profit|Projected Net Profit Agenus|AGEN - P/E Multiple|Projected Price to Earnings Ratio Agenus, Inc.|AGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Agenus Inc|AGEN - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Agenus|AGEN - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months agenusbio.com|AGEN - Earnings growth in current year|Earnings growth forecast for next year Agenus
- issuer revenue and sales details:
Summary company analytics:AGEN agenusbio.com
The success of Agenus (AGEN) depends on regulatory approval of new cancer immunotherapy methods and the effectiveness of partnership deals. By analyzing the historical P/S trend, an investor assesses the ratio of market capitalization to annual revenue, which allows for a real-time assessment of the market's reaction to inflationary risks and changes in margins, thereby determining the extent of the premium paid for future business growth.
Competitors of Agenus
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|Price-to-Revenue Multiple kiniksa.com KNSA|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|Aurinia Corp - Market Cap to Revenue Ratio|BioCryst - Market Cap to Revenue|P/S Multiple veratx.com VERA|DNTH - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Pharvaris NV PHVS|ABCL: P/S Multiple|Tourmaline (TRML) - P/S Multiple|PGEN (Precigen, Inc.) - P/S Multiple|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|UPB - Price to Sales|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM: Market Cap to Revenue Ratio|GOSS - Price-to-Revenue Ratio|Price-to-Sales Ratio KALV|SEPN: P/S Multiple|Pieris Pharma - Market Capitalization-to-Revenue Ratio|SVRA (Savara Corp) - P/S Multiple|P/S Multiple Rigel Corp|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS (astriatx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio enGene ENGN|RAPT - Market Cap to Revenue|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|tizianalifesciences.com - Market Capitalization-to-Revenue Ratio|CABA (Cabaletta Bio) - P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Market Cap to Revenue Avalo Therapeutics Inc AVTX|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|CLYM - Market Cap to Revenue|ZURA: Market Cap to Revenue|ATYR - P/S Multiple|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio IMA|STTK (Shattuck Labs Inc) - P/S Multiple|Price to Sales Equillium Bio EQ|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|P/S Multiple ATRA (Atara Bio)|Price-to-Revenue Multiple InflaRx NV|X4 Pharmaceuticals - P/S Multiple|Price to Sales Adicet Bio|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio INMB|Market Cap to Revenue BRNS|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Price-to-Revenue Coefficient akaritx.com|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|P/S Multiple Q32 Bio Inc QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Multiple Edesa Biotech Corp (EDSA)|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Ratio BOLT (Bolt Bio)|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|APVO: Price-to-Sales Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue scinai.com (SCNI)|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue TC BioPharm (Holdings) Plc|Price-to-Revenue Ratio Third Harmonic Bio, Inc
